<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661492</url>
  </required_header>
  <id_info>
    <org_study_id>06-118</org_study_id>
    <nct_id>NCT00661492</nct_id>
  </id_info>
  <brief_title>Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)</brief_title>
  <official_title>A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ImClone LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>US Oncology Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the time to progression produced by the combination of Novantrone (mitoxantrone)
      and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously
      treated with docetaxel-based chemotherapy. TTP is defined as time from the start of treatment
      date to the date the patient is first recorded as having disease progression, even in
      patients who discontinue study treatment early due to toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a nonblinded, randomized phase II study to determine the activity of Novantrone
      (mitoxantrone) with or without Erbitux (cetuximab) in patients with androgen independent
      prostate cancer (AIPC) who have been treated previously with docetaxel chemotherapy. The
      Novantrone (mitoxantrone)-only treatment arm will serve as a concurrent control arm to aid in
      the determination of the benefit of the Novantrone (mitoxantrone)-Erbitux (cetuximab)
      combination in this setting.

      Patients will be randomly assigned 2:1 to 1 of 2 treatment arms; 93 patients in Arm 1 and 47
      patients in Arm 2. A balanced randomization procedure will be performed utilizing a code list
      that will be developed prior to the study opening. Because the patients will be stratified by
      performance status (ECOG 0 and 1 vs. ECOG 2), the list will be developed to ensure a balance
      between the 2 treatment arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time to Progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>TTP will be measured from the start of treatment date to the date the patient is first recorded as having disease progression (even in patients who discontinue study treatment early due to toxicity or death due to disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year Radiographically Evident Progression-free Survival (REPFS).</measure>
    <time_frame>24 months.</time_frame>
    <description>Radiographic progression:
1) For bone scan, 2 unequivocal new lesions confirmed by a subsequent bone scan with at least 1 more new lesion; 2) Skeletal related event (eg, fracture, need for radiation to bone for pain, spinal cord compression, need for surgery to bone to prevent or treat a pathologic fracture).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR = CR + PR Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Prostate-specific Antigen (PSA) Progression</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the time from initiation of therapy until the first 25% increase from baseline in non-responders or 50% increase from nadir in responders as defined above. A minimum increase in the PSA of 5 ng/mL will be required for progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific Antigen (PSA) Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the fraction of patients with a ≥50% reduction in serum PSA confirmed by a second serum PSA at least 3 weeks later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific Antigen (PSA) Doubling Time</measure>
    <time_frame>24 months</time_frame>
    <description>PSA doubling time = [log (2)× t] ÷ [log (final PSA) - log (initial PSA)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>30 months</time_frame>
    <description>OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Androgen-independent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erbitux (cetuximab) and Novantrone (mitoxantrone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novantrone (mitoxantrone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Novantrone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate. Note: Patients may have
             either measurable or non-measurable disease.

          -  Radiographic evidence of regional or distant metastases

          -  Current evidence of progression (by PSA and/or imaging studies) despite standard
             hormonal therapy.

          -  Progression by PSA will be defined as: A rising PSA defined as: at least 2 rises in
             PSA over a reference value (PSA #1). The first rising PSA (PSA #2) must be taken at
             least 1 week after PSA #1. A third PSA (PSA #3) is required to be greater than PSA #2;
             if not, a fourth PSA (PSA #4) is required to be greater than PSA #2. Progression for
             nonmeasurable disease will be defined as 2 or more new bone lesions; for measurable
             disease, progression will be defined by standard RECIST criteria.

          -  For patients who have been on antiandrogen therapy (ie, bicalutamide, flutamide,
             etc.), patients must have discontinued anti-androgen therapy for at least 6 weeks (4
             weeks for flutamide) without evidence of an antiandrogen withdrawal response. A
             washout period will not be required for patients who did not respond to an
             antiandrogen prescribed as second line hormonal therapy. For patients whose
             progression is documented by PSA, the last required PSA must be after the required
             anti-androgen washout period (4-6 weeks as appropriate).

          -  One prior docetaxel-containing regimen. Patients must have received at least 2 doses
             in an every 3-week schedule or 6 doses on a weekly schedule of docetaxel. Patients may
             have discontinued therapy due to progression, intolerance, completion of planned
             therapy, or other reasons. Chemotherapy treatment with any second-line regimen will
             not be permitted. Patients who have been previously treated with a first-line
             docetaxel-based doublet regimen will be eligible for this study, (eg, patients treated
             on a prior first-line trial containing a docetaxel/carboplatin or other
             docetaxel-based doublet).

          -  Serum testosterone levels (See protocol for specific details) (unless surgically
             castrate). Patients must continue androgen deprivation with an LHRH agonist if they
             have not undergone orchiectomy

          -  ECOG performance status

          -  Laboratory criteria for entry:

               -  absolute neutrophil count

               -  platelets

               -  bilirubin

               -  AST or ALT

          -  Life expectancy greater than 3 months

          -  Age greater than or equal to 18 years

          -  Agree to use contraceptives while on study if sexually active, and for 2 months after
             the last dose of study drug.

          -  Has signed a Patient Informed Consent Form

          -  Has signed a Patient Authorization Form

        Exclusion Criteria:

          -  More than 1 prior chemotherapy regimen for metastatic disease

          -  Prior history of uncontrolled congestive heart failure or left ventricular ejection
             fraction (LVEF) that is less than the institution's lower limit of normal on MUGA or
             echocardiogram

          -  A second active malignancy (diagnosed within 5 years) except adequately treated
             non-melanoma skin cancer or other non-invasive or in-situ neoplasm

          -  Significant active concurrent medical illness or infection

          -  Treatment with chemotherapy for AIPC within the past 21 days

          -  Prior treatment with Novantrone (mitoxantrone)

          -  Prior therapy which specifically and directly targets the EGFR pathway

          -  Prior severe infusion reaction to a monoclonal antibody

          -  Recent myocardial infarction (within prior 6 months)

          -  Prior treatment with radionuclides, with the exception of prior treatment with
             samarium, which will be allowed provided at least 8 weeks have passed since
             administration.

          -  Is receiving concurrent immunotherapy, hormonal therapy, radiation therapy, or any
             other non-protocol therapy (excluding LHRH antagonist)

          -  Is receiving concurrent investigational therapy or has received such therapy within
             the past 30 days

          -  Has evidence of CNS involvement

          -  Has a serious uncontrolled intercurrent medical or psychiatric illness, including
             serious infection.

          -  Is unable to comply with requirements of study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark T. Fleming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Oncology Associates/US Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology Oncology Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern AZ Hematology &amp; Oncology Assoc</name>
      <address>
        <city>Sedona</city>
        <state>Arizona</state>
        <zip>86336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center-Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Internal Medicine Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Institute - New Hope</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida, P.A.</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care &amp; Hematology Specialists of Chicagoland</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Center</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Cancer Associates</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Oncology, Inc.</name>
      <address>
        <city>St. Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NH Oncology-Hematology PA</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of NNJ, P</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Cancer Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interlakes Oncology Hematology, PC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Dayton Cancer Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. -Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Central Austin Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mamie McFaddin Ward Cancer Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center at Medical City</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Charlton Cancer Ctr.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Cancer Treatment Ctr</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cancer Center - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center of Mesquite</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allison Cancer Center</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Odessa</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Regional Cancer Center</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center - Sherman</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Center-Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Northern VA Hem-Onc PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onc and Hem Associates of SW VA, Inc.</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highline Medical Oncology</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Cancer Center-Edmonds</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Cancer Center-Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest-South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists-Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Mem Hosp/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>July 31, 2013</results_first_submitted>
  <results_first_submitted_qc>October 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgen-independent prostate cancer(AIPC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between May 2008 and March 2009, 115 eligible patients were enrolled, 75 in the CMP arm and 40 in the MP arm.</recruitment_details>
      <pre_assignment_details>5 patients with Withdrew Consent and 23 patients with Failed Entry.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Novantrone+Erbitux</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Novantrone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Request</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Novantrone+Erbitux</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Novantrone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.5" spread="8.7"/>
                    <measurement group_id="B2" value="70.7" spread="8.1"/>
                    <measurement group_id="B3" value="71.2" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Progression (TTP)</title>
        <description>TTP will be measured from the start of treatment date to the date the patient is first recorded as having disease progression (even in patients who discontinue study treatment early due to toxicity or death due to disease progression.</description>
        <time_frame>24 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression (TTP)</title>
          <description>TTP will be measured from the start of treatment date to the date the patient is first recorded as having disease progression (even in patients who discontinue study treatment early due to toxicity or death due to disease progression.</description>
          <population>ITT population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="0.5" upper_limit="20.5"/>
                    <measurement group_id="O2" value="6.6" lower_limit="0.3" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Radiographically Evident Progression-free Survival (REPFS).</title>
        <description>Radiographic progression:
1) For bone scan, 2 unequivocal new lesions confirmed by a subsequent bone scan with at least 1 more new lesion; 2) Skeletal related event (eg, fracture, need for radiation to bone for pain, spinal cord compression, need for surgery to bone to prevent or treat a pathologic fracture).</description>
        <time_frame>24 months.</time_frame>
        <population>Patients who received bone scans or had bone progression only (bone pain/pathologic fracture/palliative radiation).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Radiographically Evident Progression-free Survival (REPFS).</title>
          <description>Radiographic progression:
1) For bone scan, 2 unequivocal new lesions confirmed by a subsequent bone scan with at least 1 more new lesion; 2) Skeletal related event (eg, fracture, need for radiation to bone for pain, spinal cord compression, need for surgery to bone to prevent or treat a pathologic fracture).</description>
          <population>Patients who received bone scans or had bone progression only (bone pain/pathologic fracture/palliative radiation).</population>
          <units>Probability of REPFS at 2-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.56" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.55" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>ORR = CR + PR Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.</description>
        <time_frame>24 months</time_frame>
        <population>Patients with solid tumors</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>ORR = CR + PR Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.</description>
          <population>Patients with solid tumors</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                    <measurement group_id="O2" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Prostate-specific Antigen (PSA) Progression</title>
        <description>Defined as the time from initiation of therapy until the first 25% increase from baseline in non-responders or 50% increase from nadir in responders as defined above. A minimum increase in the PSA of 5 ng/mL will be required for progression.</description>
        <time_frame>24 months</time_frame>
        <population>Patients with Prostate-specific antigen (PSA) Information</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Prostate-specific Antigen (PSA) Progression</title>
          <description>Defined as the time from initiation of therapy until the first 25% increase from baseline in non-responders or 50% increase from nadir in responders as defined above. A minimum increase in the PSA of 5 ng/mL will be required for progression.</description>
          <population>Patients with Prostate-specific antigen (PSA) Information</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.03" upper_limit="24.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.03" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-specific Antigen (PSA) Response Rate</title>
        <description>Defined as the fraction of patients with a ≥50% reduction in serum PSA confirmed by a second serum PSA at least 3 weeks later</description>
        <time_frame>24 months</time_frame>
        <population>Evaluable Population with Prostate-specific antigen (PSA) Information</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-specific Antigen (PSA) Response Rate</title>
          <description>Defined as the fraction of patients with a ≥50% reduction in serum PSA confirmed by a second serum PSA at least 3 weeks later</description>
          <population>Evaluable Population with Prostate-specific antigen (PSA) Information</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O2" value="17.6" lower_limit="6.8" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-specific Antigen (PSA) Doubling Time</title>
        <description>PSA doubling time = [log (2)× t] ÷ [log (final PSA) - log (initial PSA)]</description>
        <time_frame>24 months</time_frame>
        <population>Evaluable Population with Prostate-specific antigen (PSA) Information</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-specific Antigen (PSA) Doubling Time</title>
          <description>PSA doubling time = [log (2)× t] ÷ [log (final PSA) - log (initial PSA)]</description>
          <population>Evaluable Population with Prostate-specific antigen (PSA) Information</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="-61.3" upper_limit="62.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-2544" upper_limit="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival (PFS)</title>
        <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.</description>
        <time_frame>24 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival (PFS)</title>
          <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.</description>
          <population>ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="0.5" upper_limit="20.5"/>
                    <measurement group_id="O2" value="5.5" lower_limit="0.3" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS)</title>
        <description>OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.</description>
        <time_frame>30 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Novantrone+Erbitux</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Novantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS)</title>
          <description>OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.</description>
          <population>ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="0.5" upper_limit="24.1"/>
                    <measurement group_id="O2" value="15.7" lower_limit="0.9" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the whole treatment period, up to 30 days following last dose</time_frame>
      <desc>For treated patients only, assessed at each treatment visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Novantrone+Erbitux</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Novantrone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART, CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>GI HEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>NOSEBLEED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>FIBRILLATION ATRIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>FLUTTER ATRIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ISCHEMIA MYOCARDIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>PROSTATIC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>RECTAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>RECTAL DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>RECTAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MULTIPLE ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>WEAKNESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INFECTION BLADDER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>DEATH SUDDEN (NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FRACTURE PATHOLOGICAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PAIN BACK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PAIN PELVIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PAIN SACROILIAC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BRAIN METASTASES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BELL'S PALSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MENTAL DEFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MENTAL DETERIORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MOOD ALTERED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DISTRESS RESPIRATORY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>EFFUSION PLEURAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>EMBOLISM PULMONARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>EMBOLUS PULMONARY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>SHORTNESS OF BREATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCIDENT CEREBROVASCULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CONGESTIVE HEART FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART, CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="139" subjects_affected="48" subjects_at_risk="75"/>
                <counts group_id="E2" events="35" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>LEUCOPENIA</sub_title>
                <counts group_id="E1" events="141" subjects_affected="27" subjects_at_risk="75"/>
                <counts group_id="E2" events="23" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="50" subjects_affected="24" subjects_at_risk="75"/>
                <counts group_id="E2" events="41" subjects_affected="15" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="56" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="37" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>EPIPHORA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="29" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>GASTROESOPHAGEAL REFLUX</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DYSGUESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>RECTAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="50" subjects_affected="36" subjects_at_risk="75"/>
                <counts group_id="E2" events="34" subjects_affected="22" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="75"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>WEAKNESS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INFECTION FUNGAL</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INFECTION BLADDER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="58" subjects_affected="23" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="19" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ALKALINE PHOSPHASTASE SERUM INCREASE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>GLUCOSE BLOOD INCREASED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ALT INCREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>AST INCREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CREATININE SERUM INCREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN BACK</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>SHOULDER PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>BRUISE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>NEUROPATHY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>URINARY URGENCY/FREQUENCY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>SHORTNESS OF BREATH</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INFECTION UPPER RESPIRATORY</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="63" subjects_affected="25" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark T. Fleming</name_or_title>
      <organization>US Oncology</organization>
      <phone>757-827-9400</phone>
      <email>Mark.Fleming@USONCOLOGY.COM</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

